PHarmacist led Osteoporosis Review for optimising Medicines (PHORM)
Research type
Research Study
Full title
The development and co-design of a (person-centred) primary care (clinical) PHarmacist led Osteoporosis Review for optimising Medicines (PHORM)
IRAS ID
329218
Contact name
Andrew Sturrock
Contact email
Sponsor organisation
University of Northumbria at Newcastle
Duration of Study in the UK
1 years, 2 months, 30 days
Research summary
Background:
There is no standard practice for following up patients with osteoporosis. Patients have reported this as a problem, because of ongoing needs. Medicines optimisation is a term used to describe a person-centred approach to safe and effective medicines use, helping people obtain the best possible outcomes from their medicine.Aim:
To develop a pharmacist follow-up review in general practice to support person-centred care and medicines optimisation for people on osteoporosis medicines.Methods:
We will co-design the review with patients and healthcare professionals. We will use findings from a literature review of interventions that support patients to feel informed and adhere to osteoporosis medicines which members of this group have already undertaken on behalf of the Royal Osteoporosis Society (ROS) Bone Research Academy. The review will also be informed by an existing ROS-funded training and decision support tool (iFraP), developed for use in Fracture Liaison Services when people start medicines.We will use focus groups with patients and healthcare professionals, and extensive PPIE/Stakeholder input to explore how, where and when the review should be delivered and how to adapt and build on the existing iFraP resources for the new review. Focus groups will be held either online or face to face giving participants choice in how they take part.
We will then test the review with a small number of patients and pharmacists to make sure it works in practice. These patients (with informed consent) will participate in the model intervention which will be audio recorded and observed by a researcher. The patient and pharmacist will then take part in a 1-1 interview with the researcher to allow participants to share their views so that the intervention can be refined.
We aim to seek further funding for a full clinical trial of the new intervention in the future.
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
23/NW/0199
Date of REC Opinion
13 Jul 2023
REC opinion
Further Information Favourable Opinion